RE:RE:Moody's report: BMS, Merck, Pfizer face steep patent cliff
Because of the noise on this message board, its necessary to sometimes repeat what has already been stated - such as this Moody's report and PwC reporting that Big Pharma's "M&A "sweetspot" for 2022 is between USD $5 Billion to USD$ 15 Billion.
[ For Q2 2022 Pfizer booked revenues of USD $27.7 Billion, an increase of USD $8.8 billion, or 47%, compared to the prior year quarter, reflecting operational growth of USD $10.1 billion, or 53% increase.
The company now has the capacity to do even more as its cash holdings increased to USD $59.3 Billion (before the Arena and Biohaven M&A deals) - USD$ 41 Billion when taking into account to those deals.]
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-PFE-Earnings-Release.pdf